Cancer Research Technology
Log in Register
Menu

RMA.Trh4 Kb KO cells

Invented by Thorbald Van Hall
Invented at Leiden University and Leiden University Medical Center, Stichting Oncode Institute

Info

Catalogue Number 157678
Antigen/Gene or Protein Targets Trh4 Kb KO
Parental Line RMA
Host Mouse
Tissue Lymphatic Tissue
Disease Keywords Mouse Leukemia
Model Knock-Out
Relevance This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo‐antigen selectively presented by cells with processing defects in the classical MHC class I (MHC‐I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore can present the Trh4 peptide. Clear T cell recognition can be observed since the irrelevant MHC class I H2-Kb was knocked out.This population acts as a clear control.
Production Details Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology
Research Area Cancer
Recommended Growing Conditions Suspension cells in DMEM+8% FCS
Positive Control RMA.Trh4 Db KO cells
Notes CRISPR edited RMA cells.

Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.

This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.
Cellosaurus ID CVCL_J385

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.


Add a reference

References: 1 entry

Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.


Add a reference